Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Lepu Bio Seeks to Raise $115 Million in Hong Kong IPO

publication date: Feb 10, 2022

Lepu Biopharma of Beijing has begun taking orders for its $115 million Hong Kong IPO. The company has built a portfolio of oncology candidates that include eight products at clinical-stage, three in pre-clinical development and three combination therapies. It considers its PD-1 antibody a backbone of its development portfolio and has filed NDAs in China for two candidates. Because recent China life science IPOs have not held their value in post-IPO trading, the Lepu IPO will measure the appetite of investors for new biopharma offerings in 2022. More details....

Stock Symbol: (HK: 2157)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital